DK0830145T3 - Formuleringer omfattende leflunomid - Google Patents

Formuleringer omfattende leflunomid

Info

Publication number: DK0830145T3
Authority: DK; Denmark
Prior art keywords: leflunomide; formulations; formulation; alcohol; ratio
Prior art date: 1995-04-26

Application number

DK96912954T

Other languages

English (en)

Inventor

Donna Pruess Schwartz

Laura Kay Shawver

Original Assignee

Sugen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-26

Filing date

1996-04-17

Publication date

2000-10-09

1996-04-17 Application filed by Sugen Inc filed Critical Sugen Inc

2000-10-09 Application granted granted Critical

2000-10-09 Publication of DK0830145T3 publication Critical patent/DK0830145T3/da

Links

238000009472 formulation Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 title 1
229960000681 leflunomide Drugs 0.000 title 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
150000002634 lipophilic molecules Chemical class 0.000 abstract 1
239000008180 pharmaceutical surfactant Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Toxicology (AREA)
Pathology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Dermatology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK96912954T 1995-04-26 1996-04-17 Formuleringer omfattende leflunomid DK0830145T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/429,206 US5610173A (en)	1994-01-07	1995-04-26	Formulations for lipophilic compounds
PCT/US1996/005500 WO1996033745A1 (en)	1995-04-26	1996-04-17	Formulations for lipophilic compounds

Publications (1)

Publication Number	Publication Date
DK0830145T3 true DK0830145T3 (da)	2000-10-09

Family

ID=23702260

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96912954T DK0830145T3 (da)	1995-04-26	1996-04-17	Formuleringer omfattende leflunomid

Country Status (16)

Country	Link
US (2)	US5610173A (da)
EP (2)	EP0830145B1 (da)
JP (1)	JP2930733B2 (da)
KR (1)	KR19990008064A (da)
CN (1)	CN1182371A (da)
AT (1)	ATE193830T1 (da)
CA (1)	CA2215327C (da)
DE (1)	DE69608896T2 (da)
DK (1)	DK0830145T3 (da)
ES (1)	ES2148755T3 (da)
GR (1)	GR3034191T3 (da)
IL (1)	IL117889A0 (da)
NO (1)	NO304261B1 (da)
PT (1)	PT830145E (da)
RU (1)	RU2159110C2 (da)
WO (1)	WO1996033745A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5700823A (en) *	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
US6335356B1 (en)	1994-01-07	2002-01-01	Sugen, Inc.	Method of treating a patient by parenteral administration of a lipophilic compound
US6331555B1 (en)	1995-06-01	2001-12-18	University Of California	Treatment of platelet derived growth factor related disorders such as cancers
US6846839B1 (en)	1995-06-07	2005-01-25	Sugen, Inc.	Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US6964946B1 (en)	1995-10-26	2005-11-15	Baker Norton Pharmaceuticals, Inc.	Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1014953B1 (en)	1997-03-05	2012-04-25	Sugen, Inc.	Formulations for hydrophobic pharmaceutical agents
US6051565A (en)	1997-04-26	2000-04-18	International Phytochemistry Research Labs, Ltd.	Farnesyl-protein transferase inhibitors
US6316479B1 (en)	1997-05-19	2001-11-13	Sugen, Inc.	Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US6342593B1 (en)	1997-06-11	2002-01-29	Sugen, Inc.	Diagnosis and treatment of ALP related disorders
US7115710B2 (en) *	1997-06-11	2006-10-03	Sugen, Inc.	Diagnosis and treatment of PTP related disorders
US6388063B1 (en)	1997-06-18	2002-05-14	Sugen, Inc.	Diagnosis and treatment of SAD related disorders
US6235769B1 (en)	1997-07-03	2001-05-22	Sugen, Inc.	Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
ATE207065T1 (de) *	1997-08-08	2001-11-15	Aventis Pharma Gmbh	Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
US6753005B1 (en) *	1997-12-31	2004-06-22	Direct Therapeutics, Inc.	Method for tissue perfusion
US6495353B1 (en) *	1998-01-21	2002-12-17	Sugen, Inc.	Human orthologues of wart
US6525072B1 (en)	1998-08-31	2003-02-25	Sugen, Inc.	Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
US7064114B2 (en)	1999-03-19	2006-06-20	Parker Hughes Institute	Gel-microemulsion formulations
HUP0204069A3 (en) *	1999-12-16	2005-01-28	Teva Pharma	Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
EP1257270B1 (en)	2000-02-15	2005-04-13	Teva Pharmaceutical Industries Ltd.	A method for synthesizing leflunomide
HRP20020751B1 (hr)	2000-02-15	2011-01-31	Sugen	Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
AR042586A1 (es) *	2001-02-15	2005-06-29	Sugen Inc	3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
ATE454137T1 (de) *	2001-07-25	2010-01-15	Facet Biotech Corp	Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
JP2005508953A (ja)	2001-10-10	2005-04-07	スージェン・インコーポレーテッド	キナーゼ阻害剤としての３−［４−（置換ヘテロサイクリル）−ピロール−２−イルメチリデン］−２−インドリノン誘導体
EP1768662A2 (en)	2004-06-24	2007-04-04	Novartis Vaccines and Diagnostics, Inc.	Small molecule immunopotentiators and assays for their detection
DE102006017896A1 (de) *	2006-04-13	2007-10-25	Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg	Leflunomid enthaltende pharmazeutische Zusammensetzungen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL178596C (nl) *	1975-06-05	1986-04-16	Hoechst Ag	Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2854439A1 (de) *	1978-12-16	1980-07-03	Hoechst Ag	Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US4992271A (en) *	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
JPS60239415A (ja) *	1984-05-15	1985-11-28	Nippon Kayaku Co Ltd	エトポシド注射剤
US5268382A (en) *	1985-09-27	1993-12-07	Hoechst Aktiengesellschaft	Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
US4927638A (en) *	1986-10-08	1990-05-22	Bristol-Myers Company	Etoposide solutions
US5360611A (en) *	1988-10-03	1994-11-01	Alcon Laboratories, Inc.	Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
DD297328A5 (de) *	1989-08-18	1992-01-09	��@��k��Kk��	5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
AU649421B2 (en) *	1990-05-18	1994-05-26	Sanofi-Aventis Deutschland Gmbh	Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
FR2678833B1 (fr) *	1991-07-08	1995-04-07	Rhone Poulenc Rorer Sa	Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
GB9200275D0 (en) *	1992-01-08	1992-02-26	Roussel Lab Ltd	Chemical compounds
US5314685A (en) *	1992-05-11	1994-05-24	Agouron Pharmaceuticals, Inc.	Anhydrous formulations for administering lipophilic agents
EP0607777B1 (de) *	1993-01-08	1998-12-09	Hoechst Aktiengesellschaft	Verwendung von Leflunomid zur Hemmung von Interleukin 8
ES2124800T3 (es) *	1993-01-08	1999-02-16	Hoechst Ag	Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
ATE174219T1 (de) *	1993-01-08	1998-12-15	Hoechst Ag	Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
TW406020B (en) *	1993-09-29	2000-09-21	Bristol Myers Squibb Co	Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5700823A (en) *	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers

1995
- 1995-04-26 US US08/429,206 patent/US5610173A/en not_active Expired - Fee Related
1996
- 1996-04-12 IL IL11788996A patent/IL117889A0/xx unknown
- 1996-04-17 EP EP96912954A patent/EP0830145B1/en not_active Expired - Lifetime
- 1996-04-17 DK DK96912954T patent/DK0830145T3/da active
- 1996-04-17 CA CA002215327A patent/CA2215327C/en not_active Expired - Fee Related
- 1996-04-17 WO PCT/US1996/005500 patent/WO1996033745A1/en not_active Ceased
- 1996-04-17 RU RU97119293/14A patent/RU2159110C2/ru active
- 1996-04-17 EP EP99119091A patent/EP0997153A1/en not_active Withdrawn
- 1996-04-17 DE DE69608896T patent/DE69608896T2/de not_active Expired - Fee Related
- 1996-04-17 AT AT96912954T patent/ATE193830T1/de not_active IP Right Cessation
- 1996-04-17 PT PT96912954T patent/PT830145E/pt unknown
- 1996-04-17 ES ES96912954T patent/ES2148755T3/es not_active Expired - Lifetime
- 1996-04-17 KR KR1019970707588A patent/KR19990008064A/ko not_active Abandoned
- 1996-04-17 CN CN96193486A patent/CN1182371A/zh active Pending
- 1996-04-17 JP JP8532614A patent/JP2930733B2/ja not_active Expired - Lifetime
1997
- 1997-03-06 US US08/813,377 patent/US5783592A/en not_active Expired - Fee Related
- 1997-10-22 NO NO974868A patent/NO304261B1/no not_active IP Right Cessation
2000
- 2000-08-14 GR GR20000401885T patent/GR3034191T3/el unknown

Also Published As

Publication number	Publication date
EP0830145A1 (en)	1998-03-25
EP0997153A1 (en)	2000-05-03
RU2159110C2 (ru)	2000-11-20
EP0830145B1 (en)	2000-06-14
US5783592A (en)	1998-07-21
ATE193830T1 (de)	2000-06-15
ES2148755T3 (es)	2000-10-16
NO974868L (no)	1997-10-22
CN1182371A (zh)	1998-05-20
DE69608896T2 (de)	2001-01-18
CA2215327A1 (en)	1996-10-31
DE69608896D1 (de)	2000-07-20
IL117889A0 (en)	1996-08-04
NO304261B1 (no)	1998-11-23
NO974868D0 (no)	1997-10-22
US5610173A (en)	1997-03-11
AU5560496A (en)	1996-11-18
JPH10511683A (ja)	1998-11-10
MX9708195A (es)	1998-07-31
AU700423B2 (en)	1999-01-07
CA2215327C (en)	1999-07-27
JP2930733B2 (ja)	1999-08-03
PT830145E (pt)	2000-12-29
KR19990008064A (ko)	1999-01-25
GR3034191T3 (en)	2000-11-30
WO1996033745A1 (en)	1996-10-31

Publication	Publication Date	Title
ES2148755T3 (es)	2000-10-16	Formulaciones que contienen leflunomida.
IT1272992B (it)	1997-07-01	Formulazioni galeniche contenenti macrolidi.
SE9503143D0 (sv)	1995-09-12	New preparation
CA2301017A1 (en)	1999-03-11	Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
DE59602775D1 (de)	1999-09-23	6-Dimethylaminomethyl-1-phenyl-cyclo-hexanverbindungen als pharmazeutische Wirkstoffe
ATE188961T1 (de)	2000-02-15	1-phenyl-2-dimethylaminomethyl-cyclohexan-1- olverbindungen als pharmazeutische wirkstoffe
MX9307686A (es)	1994-06-30	Preparacion de liberacion sostenida.
DE69824277D1 (de)	2004-07-08	Stabile medizinische zusammenstellungen die 4,5-epoxymorphinanderivate enthalten
NZ318282A (en)	2000-01-28	Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
ITRM920383A1 (it)	1993-11-22	Preparati liposomici contenenti un composto allilamminico come agente farmacologicamente attivo
DE59800863D1 (de)	2001-07-19	Transdermale, orale und intravenöse zubereitungen von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon
IT1264856B1 (it)	1996-10-17	Composizione farmaceutica ad attivita' analgesica
AU5895990A (en)	1991-01-17	Stable tretinoin emulsified cream formulations
AU629445B2 (en)	1992-10-01	Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
BR0011864A (pt)	2004-07-20	Formulações farmacêuticas
ATE285782T1 (de)	2005-01-15	Pharmazeutische zusammensetzungen die ein alkylaryl polyether alkohol polymer enthalten
ATE263576T1 (de)	2004-04-15	Prostaglandine und benzylalcohol enthaltende lösung
GB9522885D0 (en)	1996-01-10	Improvements in or relating to organic compositions
ES2128122T3 (es)	1999-05-01	Nuevas formulaciones liquidas.
DE69023241D1 (de)	1995-11-30	Ionophore enthaltende abgabevorrichtung.
CO4340678A1 (es)	1996-07-30	Formulaciones para agentes farmaceuticos administrados en forma oral
ES2091710B1 (es)	1997-08-01	Composicion insecticida de metomilo y endosulfan de alta concentracion y procedimiento de preparacion.